Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Trends in tuberculosis treatment duration].

Presse medicale (Paris, France : 1983) - 1 Nov 2006

Veziris Nicolas, Aubry Alexandra, Truffot-Pernot Chantal

Abstract excerpt

The two principal characteristics of tuberculosis treatment are its length (several months) and the need to use several antibiotics simultaneously (multiple drug therapy). Multiple drug therapy is intended to prevent the selection of resistant mutants at the beginning of treatment, when the bacilli population is largest. The length of treatment is due to dormant bacilli, which are much more difficult for...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibiotics, Antitubercular
Share to Antitubercular Agents
Share to Drug Resistance, Multiple, Bacterial

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Isoniazid

Share to Pyrazinamide

Share to Rifampin

Share to Tuberculosis

Share to Tuberculosis, Multidrug-Resistant

Source

Identifiers

PMID: 17086138
DOI: 10.1016/S0755-4982(06)74895-3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Trends in tuberculosis treatment duration].PMID 17086138Read ↗

The past, present and future of tuberculosis treatment.Semantic proximity Read ↗

Comparison of treatment duration for drug resistant pulmonary tuberculosis with vs. without type 2 diabetes mellitusSemantic proximity Read ↗

The chemotherapy of tuberculosis: past, present and future [State of the art]Semantic proximity Read ↗

[Treatment and retreatment of tuberculosis].Semantic proximity Read ↗

[Present trends of drug-resistant tuberculosis and how to manage it by mycobacterial laboratories].Semantic proximity Read ↗

Treating tuberculosis with high doses of anti-TB drugs: mechanisms and outcomes.Semantic proximity Read ↗

[Bacteriologic basis for the treatment of tuberculosis].Semantic proximity Read ↗

Mycobacterium tuberculosis precursor rRNA as a measure of treatment-shortening activity of drugs and regimensSemantic proximity Read ↗

Therapy for Mycobacterium kansasii Infection: Beyond 2018Semantic proximity Read ↗

Prevention of drug resistance by combined drug treatment of tuberculosis.Semantic proximity Read ↗

Linezolid Kills Acid-Phase and Nonreplicative-Persister-Phase Mycobacterium tuberculosis in a Hollow-Fiber Infection ModelSemantic proximity Read ↗

In vitro antimycobacterial activity of 2-(((2-hydroxyphenyl)amino)methylene)-5,5-dimethylcyclohexane-1,3-dione: a new chemical entity against Mycobacterium tuberculosis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.